证券代码：688526 证券简称：科前生物 公告编号：2025-028 武汉科前生物股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/6/13 | 2025/6/16 | 2025/6/16 | 1. 发放年度：2024年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东 （公司回购专用证券账户除外）。 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等有关规定，公司回购专用证券账户中的股份不享有股东会表 是否涉及差异化分红送转：是 每股分配比例 每股现金红利0.43元（含税） 相关日期 一、 通过分配方案的股东大会届次和日期 本次利润分配预案经公司2025年 5月 19 日的2024年年度股东大会审议通 ...

Investment Rating - The report maintains a "Recommendation" rating for the animal health industry, expecting it to outperform the benchmark index by over 5% in the next 3-6 months [79]. Core Insights - The report highlights significant growth in vaccine approvals for circular, pseudorabies, and diarrhea vaccines, with notable year-on-year increases [7][8]. - The animal drug raw material market shows a continued strong performance in macrolide products, with price indices reflecting a structural differentiation among various products [52][53]. - The overall demand for animal health products is expected to recover, driven by improved profitability in the breeding sector and the introduction of new products [68][69]. Summary by Sections Vaccine Approvals - In April, major vaccine varieties for pigs showed substantial year-on-year growth, with circular vaccine up by 71.2%, pseudorabies vaccine by 73.3%, and diarrhea vaccine by 220% [7][8]. - Cumulative data from January to April indicates most vaccine types experienced significant growth, particularly in pig vaccines, with circular vaccine up by 52.3% and pseudorabies vaccine by 48.2% [8][9]. Raw Material Prices - As of the end of April, the Veterinary Pharmaceutical Index (VPI) was 69.2, reflecting a 5.6% increase from the previous month and a 13.4% increase year-on-year [52][53]. - Prices for macrolide products such as Tylosin, Tylvalosin, and Tilmicosin have shown strong performance, with increases of 10.1%, 17.6%, and 15.4% respectively compared to the end of March [53][54]. Market Outlook - The report anticipates a stable upward trend in the demand for animal health products, supported by a robust breeding sector and ongoing product innovation [68][69]. - The competitive landscape is expected to lead to a dual recovery in performance and valuation for the sector, with a focus on larger companies that can leverage their financial strength and product diversity [69][70]. Investment Recommendations - The report suggests focusing on companies such as Reap Bio, Kexin Bio, and others, which are well-positioned to benefit from the anticipated market recovery [68][70].

Summary of Conference Call on Pet Industry and Companies Industry Overview - The pet industry is experiencing rapid growth, with an annual compound growth rate of approximately 10% driven by increasing pet ownership and the rising penetration of pet food products [2][10] - The pet medical market is projected to reach 80-90 billion by 2025, making it the second-largest segment after pet food [10] Key Companies and Their Performance 1. Guibao Pet - Guibao Pet's self-owned brand has shown strong performance, with revenue of approximately 3.5 billion, accounting for nearly 70% of total revenue, and a net profit margin of 12% [1][4] - The high-end cat food brand, Fliegate, achieved a growth rate of 100% last year and maintained the same growth rate in Q1 of this year [4] - Guibao is expected to become a leading enterprise with projected revenues nearing 25 billion and net profits around 5 billion in the medium to long term [1][4] 2. Zhongchong Co., Ltd. - Zhongchong Co., Ltd. experienced a significant growth of nearly 200%-300% from its previous low, with total revenue from its three domestic brands (Wangpi, Lingxian, and ZIP) reaching 1.4 billion last year [5] - The company aims for overseas revenue of 400 million this year, maintaining a growth rate of 50% [5][6] - The net profit margin for its North American subsidiary is reported to be between 15%-20% [6] 3. Petty Co., Ltd. - Petty's overseas business accounts for a significant portion of its operations, with a focus on exports to the U.S. [8] - Domestic revenue was approximately 290 million last year, with a target of 400-450 million this year, reflecting a growth of over 40% [9] - The company is adjusting its product lines and plans to launch new baked grain products in Q2 and Q3 [8][9] Market Dynamics and Future Outlook - The pet medical sector is characterized by a lack of dominant players, with foreign brands leading in pharmaceuticals and vaccines, indicating substantial room for domestic companies to grow [11][12] - The average medical expenses for pets have doubled due to increasing age, leading to a rigid demand for medical services [10] - Companies like Ruipuhua and KQ Bio are recommended for their comprehensive industry layouts and potential for growth in the pet medical field [13][15] Additional Insights - The overall pet industry is expected to continue expanding, with self-owned brands focusing on product innovation to enhance profitability [2] - The competitive landscape in the pet medical sector is still developing, with many local companies poised to capture market share as the industry matures [12] - Other companies to watch include Baisha Technology, Biological Shares, and Zhongmu Shares, which have varying degrees of involvement in the pet medical sector [18]

Group 1 - Hongjing Technology signed a service contract for an intelligent computing project with a total amount of 597 million yuan, valid for 5 years [1] - Weifu High-Tech's subsidiary invested 220 million yuan to establish a joint venture with Shanghai Baolong Automotive Technology [2] - Zhongshan Public received approval for the registration of short-term financing bonds amounting to 2 billion yuan and medium-term notes of 3 billion yuan [3] Group 2 - Lianhua Technology established a venture capital fund with a total commitment of 200 million yuan, contributing 100 million yuan as a limited partner [4] - Changan Technology's shareholder signed an agreement to transfer 6.27% of the company's shares to Hefei State Capital Venture Investment [6] - Hangzhou Garden announced a cash dividend of 0.5 yuan per 10 shares, totaling 6.62 million yuan [8] Group 3 - Huamao Technology plans to acquire 100% equity of Fuchuang Youyue, leading to a temporary suspension of its stock [9] - Zhuojin Co. won a bid for a soil remediation project in Hefei with a contract value of 67.68 million yuan [10] - Shanghai Pharmaceuticals received FDA approval for two drugs, enhancing its product portfolio [10] Group 4 - Fuxing Pharmaceutical's senior vice president resigned for personal reasons [12] - Baolong Technology's subsidiary plans to invest 180 million yuan in a joint venture [13] - ST Zhongdi intends to utilize surplus funds from a project company, with a maximum of 106 million yuan [14] Group 5 - Nanchao Food reported a significant decline in net profit for April, down 82.14% year-on-year [16] - Changshan Pharmaceutical received a drug registration certificate in Belarus for a new product [18] - Nanshan Aluminum established a wholly-owned subsidiary for photovoltaic energy projects with an investment of 5 million yuan [20] Group 6 - Bozhong Precision announced the resignation of a director and deputy general manager [22] - Xinjiang Jiaojian won a bid for a highway construction project valued at 451 million yuan [23] - Guangzhou Restaurant declared a cash dividend of 0.48 yuan per share, totaling 273 million yuan [25] Group 7 - Weili Medical's subsidiary obtained a medical device operating license, allowing it to engage in wholesale activities [27] - New Australia Co. announced a cash dividend of 0.3 yuan per share, totaling 219 million yuan [28] - Lianhua Technology's subsidiary entered the new third board innovation layer [29] Group 8 - Huaxi Energy's chairman resigned due to personal reasons [31] - Yipin Hong plans to use up to 500 million yuan of idle funds for cash management [33] - Shouhua Gas intends to purchase bauxite resources through market means [34] Group 9 - Jincheng signed a service agreement for underground mining operations at the Komakau Copper Mine, valued at approximately 805 million USD [34] - Wanrun New Energy signed a supply contract with CATL for lithium iron phosphate products, with a total supply of about 1.32 million tons [35] - Weili plans to transfer 100% equity of a subsidiary to Chengfa Environment for 100 million yuan [36] Group 10 - Zhenlei Technology's subsidiary received government subsidies of 2.21 million yuan, positively impacting profits [38] - Weir shares plan to change their name to "Haowei Group" to reflect strategic direction [39] - YTO Express reported a revenue increase of 16.32% in April, totaling 5.755 billion yuan [39]

Core Viewpoint - The animal vaccine sector has shown a significant increase, with a 4.00% rise, ranking third among concept sectors, driven by notable gains in several stocks [1][2]. Group 1: Sector Performance - As of May 20, the animal vaccine concept increased by 4.00%, with 19 stocks rising, including *ST Xianfeng, which hit the daily limit, and others like Kexing Pharmaceutical, Ruipu Biological, and Kanghua Biological, which rose by 15.56%, 8.41%, and 6.70% respectively [1][2]. - The animal vaccine sector was among the top-performing sectors, alongside cultivated diamonds and pet economy, which rose by 4.10% and 4.08% respectively [2]. Group 2: Capital Inflow - The animal vaccine sector saw a net inflow of 67 million yuan, with 13 stocks receiving net inflows, and 6 stocks attracting over 10 million yuan in net inflows [2]. - Jinhe Biological led the net inflow with 36.88 million yuan, followed by Kexing Pharmaceutical, Dabeinong, and Plk, which received net inflows of 15.38 million yuan, 13.79 million yuan, and 13.60 million yuan respectively [2][3]. Group 3: Capital Flow Ratios - Stocks such as *ST Xianfeng, Kexing Pharmaceutical, and KQ Biotech had the highest net inflow ratios, at 14.17%, 6.56%, and 5.52% respectively [3]. - The top stocks in terms of capital inflow included Jinhe Biological with a turnover rate of 18.22% and a daily increase of 4.40%, and Kexing Pharmaceutical with a turnover rate of 3.46% and a daily increase of 15.56% [3][4].

Core Viewpoint - The article summarizes significant announcements from various listed companies in the Shanghai and Shenzhen stock markets, providing insights for investors on recent corporate actions and developments. Group 1: Corporate Announcements - Kweichow Moutai's shareholders approved a profit distribution plan for 2024, proposing a cash dividend of 276.24 yuan per 10 shares, totaling 34.672 billion yuan [3] - Weir Shares plans to change its name to "Haowei Group" and its stock abbreviation to "Haowei Group," pending shareholder approval [4] - Weili intends to transfer 100% equity of its subsidiary Dunhua Zhongneng to Chengfa Environment for a total consideration of approximately 323 million yuan [6] - Wanrun New Energy signed a business cooperation agreement with CATL to supply lithium iron phosphate products, with an estimated total supply of about 1.3231 million tons from 2025 to 2030 [7] - Shouhua Gas plans to purchase bauxite resources through market means, with a financing application of up to 2 billion yuan [8] Group 2: Regulatory and Compliance - Gao Neng Environment received an administrative regulatory decision from the Beijing Securities Regulatory Bureau due to insufficient impairment testing and inaccurate disclosures [9] - ST Shilong applied to revoke its other risk warning status, indicating compliance with relevant regulations [14] Group 3: Mergers and Acquisitions - Huixin Electronics plans to acquire 67.91% of Baode Computer through a combination of cash and stock issuance, enhancing its position in the IT infrastructure sector [19] - Kangping Technology intends to acquire 100% of Sulu Electronics for 198 million yuan to expand its electric tools business [23] - Xinjiang Haoyuan plans to change its name to "Wanqing Energy" to better reflect its business structure [26] Group 4: Financing and Investments - Shanghai Xinyang plans to invest 30 million yuan in the establishment of the Qixin Fund, focusing on high-tech sectors [12] - Taihe Co. intends to invest up to 150 million USD (approximately 1.082 billion yuan) in a pesticide and functional chemicals project in Egypt [28] Group 5: Strategic Partnerships and Contracts - Dongzhu Ecology signed a 3.5 billion yuan EPC contract for land consolidation in Laos [30] - Youa Co. signed a strategic cooperation framework agreement with Changsha Guokong Capital and Tsinghua Electronics Institute to promote the semiconductor industry [32] Group 6: Shareholder Actions - Wanfeng Co. plans to reduce its stake by up to 1.75% through block trading [35] - Tuoershi's controlling shareholder intends to reduce its stake by up to 2% [36]

证券代码：688526 证券简称：科前生物 公告编号：2025-026 武汉科前生物股份有限公司 第四届监事会第九次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 一、监事会会议召开情况 武汉科前生物股份有限公司（下称"公司"）于 2025 年 5 月 19 日以现场和通讯相结合的形式召开第四届监事会第九次会议（下称 "本次会议"）。本次会议通知于 2025 年 5 月 14 日以邮件、电话的 方式向各位监事发出，本次会议由监事会主席吴斌先生主持，本次会 议应参与表决监事 3 人，实际参与表决监事 3 人。本次会议的召集、 召开程序均符合《公司法》、《证券法》等法律、法规和规范性文件 以及《公司章程》的规定。 二、监事会会议审议情况 经与会监事审议，作出决议如下： (一）审议通过《关于公司与华中农大签订合作研发协议暨关联 交易的议案》 监事会认为：公司本次签订合作研发协议暨关联交易符合公司整 体发展方向，本次关联交易的审批程序合法合规，不存在损害公司及 股东利益的情形。 具体内容详见公司于同日刊登在上海证券 ...

证券代码：688526 证券简称：科前生物 公告编号：2025-025 武汉科前生物股份有限公司 2024年年度股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 5 月 19 日 （二） 股东会召开的地点：湖北武汉东湖新技术开发区高新二路 419 号科前生 物二楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 57 | | --- | --- | | 普通股股东人数 | 57 | | 2、出席会议的股东所持有的表决权数量 | 343,728,273 | | 普通股股东所持有表决权数量 | 343,728,273 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 74.0927 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 74.0927 | 注 ...

根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上 海证券交易所科创板股票上市规则》等有关法律、法规和规范性文件 以及《武汉科前生物股份有限公司章程》（下称"《公司章程》"） 等有关规定。我们作为武汉科前生物股份有限公司（以下简称"公司"） 的独立董事，基于独立判断的立场，本着对公司、全体股东负责的态 度，秉持实事求是的原则，对公司第四届董事会第十次会议审议的《关 于公司拟与华中农大签订合作研发协议暨关联交易的议案》进行了认 真调查和核查，并发表独立意见如下： 公司本次拟与华中农大签订合作研发协议，有利于提高公司在生 物制品领域的核心竞争力，加快公司在生物制品行业的发展，并且履 行了《公司章程》、《合作研发管理制度》以及《华中农业大学与武汉 科前生物股份有限公司之合作研发框架协议》规定的程序。本次交易 构成关联交易，本次关联交易表决程序合法，交易价格公允，上述交 易不存在损害公司、全体股东的情形。我们一致同意本次公司与华中 农大签订合作研发协议事项。 独立董事：罗飞 王宏林 王晖 2025 年 5 月 19 日 武汉科前生物股份有限公司 独立董事关于第四届董事会第十次会议 相关事项的独立意见 ...

重要内容提示： 关联交易简要内容：武汉科前生物股份有限公司（下称"科 前生物"或"公司"）经与华中农业大学（下称"华中农大"）竞争 性谈判，取得了"猪传染性胸膜肺炎-链球菌病-巴氏杆菌病"三联灭 活疫苗、"猪圆环病毒病、革拉瑟氏病、链球菌病、支原体肺炎"四 联亚单位疫苗两个项目的合作研发，现拟与华中农大签订联合开发协 议书，公司就以上两个研发项目一共需向华中农大支付 400 万元人民 币。合作研发项目产生的技术成果及知识产权归公司及华中农大共同 所有； 本次交易构成关联交易，不构成《上市公司重大资产重组管 理办法》规定的重大资产重组； 证券代码：688526 证券简称：科前生物 公告编号：2025-027 武汉科前生物股份有限公司 关于拟与华中农大签订合作研发协议暨关联交易的 自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 本次关联交易实施不存在重大法律障碍； 本次关联交易已经公司第四届董事会独立董事 2025 年第三次 会议、第四届董事会第十次会议及第四届监事会第九次会议审议通过， 本事项无需提交股东大 ...